Buying time for the insulin programmes
On 30 September 2026, Arecor Therapeutics (LSE:AREC) published its interim results and, on the same day, launched and completed a placing to raise new capital. The timing reflects a simple reality for a small biotechnology company: its existing cash was projected to last only until April 2027. Why Arecor raised the money, what it intends to fund and what risks remain are the subject of this article.
The business
Arecor Therapeutics plc is a biopharmaceutical company quoted on AIM under the ticker AREC. It uses a proprietary formulation technology to develop reformulated versions of therapeutic products, with a focus on diabetes. Its lead programmes are ultra-concentrated insulins designed for automated insulin delivery systems and pumps: AT278, a U500 insulin, and AT290, a U200 insulin. The company also earns income through licensing, including a Royalty arrangement with Ligand Pharmaceuticals linked to its AT220 and AT292 programmes. Dr Sarah Howell is chief executive.
The fundraising
On 30 September 2026, Arecor announced a proposed fundraising of up to £5.13 million, comprising a £5.0 million institutional placing and a retail offer of up to £130,000. Later that day it confirmed that the placing had raised £5.0 million gross through the issue of 7,352,941 shares at 68 pence each, which the company said was a 1.9% premium to the 60-day volume-weighted average price. The new shares represent roughly 20% of the existing share Capital on full subscription. Admission was expected on or before 6 October 2026.
The company said net proceeds of about £4.5 million would extend its cash runway to December 2027, compared with April 2027 before the raise. Around 59% is allocated to working capital, 23% to R&D including intellectual property, 14% to Phase 2-enabling chemistry, Manufacturing and controls work, and 4% to an oral delivery platform. Arecor identified two value inflection points: concluding Partnership negotiations, currently at term sheet stage with several insulin pump manufacturers, and starting Phase 2 studies combining its insulins with automated delivery systems. It also noted an existing co-development partnership with Sequel MedTech for AT278, signed in September 2025, under which each party committed up to US$1.3 million.
Interim financial performance
The interim results for the six months to 30 June 2026 showed Revenue of £0.2 million, down from £1.0 million, with other Operating Income of £0.2 million. R&D spending increased to £1.9 million from £1.3 million, while selling, general and administrative costs fell to £1.5 million from £1.7 million. The operating loss widened to £3.2 million and the loss after tax was £3.0 million. Cash and short-term investments were £3.2 million at 30 June 2026.
The company reported a US$0.5 million payment from Ligand in the half and a further US$0.5 million afterwards, with US$3 million tied to commercial milestones. It said the US Food and Drug Administration had given positive feedback on a planned Phase 2 design for AT290, a six-week crossover study in about 90 people with type 1 or type 2 diabetes. For 2026 it guided to revenue of about £0.3 million and a loss of about £5.5 million.
Risks and uncertainties
Even after the raise, the runway extends only to December 2027, so further funding or partnership income will probably be needed to complete clinical development. Partnership talks are not concluded and may not result in agreements. Clinical Trials can Fail or be significantly delayed, and dilution from future share placings remains a consideration for shareholders.
Conclusion
Arecor raised £5 million to extend its cash runway from April to December 2027 and to fund work that prepares its concentrated insulins for Phase 2 studies. The company's progress now depends on securing pump-maker partnerships and moving AT278 and AT290 into the clinic.






Please wait processing your request...